{"id":66811,"date":"2026-06-20T03:25:11","date_gmt":"2026-06-20T03:25:11","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/66811\/"},"modified":"2026-06-20T03:25:11","modified_gmt":"2026-06-20T03:25:11","slug":"astrazeneca-lseazn-stock-fair-value-edges-lower-after-pipeline-and-pricing-debate-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/66811\/","title":{"rendered":"AstraZeneca (LSE:AZN) Stock Fair Value Edges Lower After Pipeline And Pricing Debate"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St.<\/p>\n

AstraZeneca is in focus after analysts trimmed their fair value estimate for the stock slightly from \u00a3165.09 to \u00a3164.85, signaling a measured shift in valuation work rather than a sharp rethink. That adjustment sits alongside fresh commentary on how regulators, pricing decisions and recent advisory outcomes could shape the company\u2019s growth options, execution risk and pipeline assumptions. As you read on, you will see how these moving parts fit together so you can track the evolving analyst story around AstraZeneca more closely.<\/p>\n

Stay updated as the Fair Value for AstraZeneca<\/a> shifts by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on AstraZeneca.<\/p>\n

What Wall Street Has Been Saying \ud83d\udc02 Bullish Takeaways <\/p>\n

Citi, Morgan Stanley and Guggenheim each raised their AstraZeneca price targets, which points to a group of large firms seeing support for the current valuation framework even after recent news flow.<\/p>\n

DZ Bank moved to a more positive stance on AstraZeneca, suggesting that, for some European research desks, the long term growth profile and pipeline are still viewed as constructive.<\/p>\n

Jefferies highlighted the FDA approval of Baxfendy as the first aldosterone synthase inhibitor, which gives AstraZeneca another approved product and added clarity on label, pricing and payer access for this therapy.<\/p>\n

\ud83d\udc3b Bearish Takeaways <\/p>\n

Jefferies flagged the ODAC vote against AstraZeneca’s SERENA 6, which reinforces execution risk around certain pipeline programs and keeps some pressure on how investors think about future oncology contributions.<\/p>\n

Commentary around Baxfendy also pointed out that approval may be “incrementally constructive” for Mineralys Therapeutics, which reminds investors that AstraZeneca faces competitive considerations even in newer mechanistic areas.<\/p>\n

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!<\/a><\/p>\n

\"LSE:AZN<\/a> LSE:AZN 1-Year Stock Price Chart <\/p>\n

We’ve flagged 2 risks for AstraZeneca. See which could impact your investment.<\/a><\/p>\n

What’s in the News <\/p>\n

The U.S. FDA approved AstraZeneca\u2019s TRUQAP with abiraterone and prednisone as the first targeted therapy for adults with PTEN deficient metastatic hormone sensitive or androgen pathway modulation naive prostate cancer, supported by CAPItello 281 data and a companion diagnostic to identify eligible patients.<\/p>\n

AstraZeneca announced a planned US$50b investment to expand its U.S. manufacturing and R&D footprint, after completing the largest market cap transfer in New York Stock Exchange history, and highlighted an internal goal of reaching US$80b in revenue by 2030.<\/p>\n

The company advanced oral GLP 1 agonist elecoglipron into a broad phase 3 program in obesity and Type 2 diabetes, following phase 2b data on weight loss, HbA1c and cardiometabolic markers, and outlining multiple EMBOLD and ELUMINATE trials.<\/p>\n

AstraZeneca highlighted growing use of artificial intelligence in R&D, with CEO Pascal Soriot saying an in house AI agent is already used to estimate phase 3 success probabilities in drug development to target more efficient trials and lower failure rates.<\/p>\n

Story Continues <\/p>\n

How This Changes the Fair Value For AstraZeneca <\/p>\n

Fair value estimate for AstraZeneca adjusted from \u00a3165.09 to \u00a3164.85.<\/p>\n

Assumed long term annual dollar revenue growth shown as unchanged at 6.38%.<\/p>\n

Projected net profit margin updated from 22.57% to 22.96%.<\/p>\n

Future P\/E multiple in the model reduced from 25.83x to 25.09x.<\/p>\n

Discount rate used in the valuation effectively unchanged at 7.38%.<\/p>\n

Never Miss an Update: Follow The Narrative <\/p>\n

Narratives connect AstraZeneca\u2019s business story to analyst forecasts and a fair value estimate, updating as new approvals, data and policy changes come through. They help you see how individual headlines feed into a bigger, long term view.<\/p>\n

Head over to the Simply Wall St Community and follow the Narrative on AstraZeneca<\/a> to stay up to date on:<\/p>\n

How a broad late stage pipeline in oncology, rare diseases and cardiovascular or metabolic therapies could support future revenue and earnings.<\/p>\n

What ongoing investment in technologies like antibody drug conjugates, bispecifics, mRNA and AI enabled trials might mean for development timelines and margins.<\/p>\n

Key risks from reliance on blockbuster drugs, potential price controls in markets such as China, and high R&D spend if new launches do not offset patent expiries and competition.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include AZN.L<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":41332,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,1839,20684,22093],"class_list":["post-66811","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-fair-value","tag-fda-approval","tag-individual-investors"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116780304552040251","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/66811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=66811"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/66811\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/41332"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=66811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=66811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=66811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}